BiVictriX Therapeutics secures Innovate UK grant to advance ovarian cancer treatment

BiVictriX Therapeutics secures Innovate UK grant to advance ovarian cancer treatment

BiVictriX Therapeutics plc (AIM: BVX), a pioneering drug discovery and development company, has announced receiving a substantial grant of £0.37 million from Innovate UK. This grant is earmarked for accelerating the preclinical development of BiVictriX’s promising new drug, BVX002, which is designed to target ovarian cancer treatment through a novel approach using bispecific antibody drug […]

BiVictriX Therapeutics receives FDA orphan drug designation for BVX001 in AML

BiVictriX Therapeutics receives FDA orphan drug designation for BVX001 in AML

BiVictriX Therapeutics plc (AIM: BVX), a prominent UK-based biotechnology firm, has reached a pivotal regulatory milestone as the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead asset, BVX001. This designation is for the treatment of Acute Myeloid Leukaemia (AML), a critical area with substantial unmet medical needs. This […]